Last reviewed · How we verify

TISSEEL VH fibrin sealant

Baxter Healthcare Corporation · Phase 3 active Small molecule

TISSEEL VH fibrin sealant is a Fibrin sealant Small molecule drug developed by Baxter Healthcare Corporation. It is currently in Phase 3 development for Hemostasis and tissue sealing during surgical procedures, Control of bleeding in cardiovascular, general, and orthopedic surgery.

TISSEEL VH is a fibrin sealant that mimics the final step of the coagulation cascade to form a stable fibrin clot for hemostasis and tissue sealing.

TISSEEL VH is a fibrin sealant that mimics the final step of the coagulation cascade to form a stable fibrin clot for hemostasis and tissue sealing. Used for Hemostasis and tissue sealing during surgical procedures, Control of bleeding in cardiovascular, general, and orthopedic surgery.

At a glance

Generic nameTISSEEL VH fibrin sealant
SponsorBaxter Healthcare Corporation
Drug classFibrin sealant
TargetFibrinogen; Thrombin substrate
ModalitySmall molecule
Therapeutic areaSurgery/Hemostasis
PhasePhase 3

Mechanism of action

TISSEEL VH consists of two components—human fibrinogen and human thrombin—that when combined activate the coagulation cascade to produce fibrin monomers, which polymerize into a stable clot. This provides both hemostatic control and tissue adhesion properties. The product is used topically during surgery to seal tissues, control bleeding, and promote wound healing.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TISSEEL VH fibrin sealant

What is TISSEEL VH fibrin sealant?

TISSEEL VH fibrin sealant is a Fibrin sealant drug developed by Baxter Healthcare Corporation, indicated for Hemostasis and tissue sealing during surgical procedures, Control of bleeding in cardiovascular, general, and orthopedic surgery.

How does TISSEEL VH fibrin sealant work?

TISSEEL VH is a fibrin sealant that mimics the final step of the coagulation cascade to form a stable fibrin clot for hemostasis and tissue sealing.

What is TISSEEL VH fibrin sealant used for?

TISSEEL VH fibrin sealant is indicated for Hemostasis and tissue sealing during surgical procedures, Control of bleeding in cardiovascular, general, and orthopedic surgery.

Who makes TISSEEL VH fibrin sealant?

TISSEEL VH fibrin sealant is developed by Baxter Healthcare Corporation (see full Baxter Healthcare Corporation pipeline at /company/baxter-healthcare-corporation).

What drug class is TISSEEL VH fibrin sealant in?

TISSEEL VH fibrin sealant belongs to the Fibrin sealant class. See all Fibrin sealant drugs at /class/fibrin-sealant.

What development phase is TISSEEL VH fibrin sealant in?

TISSEEL VH fibrin sealant is in Phase 3.

What are the side effects of TISSEEL VH fibrin sealant?

Common side effects of TISSEEL VH fibrin sealant include Infection at surgical site, Hematoma formation, Seroma, Allergic reaction.

What does TISSEEL VH fibrin sealant target?

TISSEEL VH fibrin sealant targets Fibrinogen; Thrombin substrate and is a Fibrin sealant.

Related